Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Reynes

Showing results (111-120 of 200) with videos related to

Pageof 20
Sort By:
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2010
Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial)Sébastien Gallien, Valérie Journot, Willy Rozenbaum, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2005
CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strainsYea-Lih Lin, Pierre Portales, Michel Segondy, et al.
Clinical Immunology (Orlando, Fla.)|May 4, 2002
Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cellsAnne Marie Fournier, Jean-Michel Fondere, Catherine Alix-Panabieres, et al.
Immunologic Research|May 3, 2021
Cytokine response following perturbation of the cervicovaginal milieu during HPV genital infectionChristian Selinger, Massilva Rahmoun, Carmen Lia Murall, et al.
Nature|March 16, 2017
CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent provirusesBenjamin Descours, Gaël Petitjean, José-Luis López-Zaragoza, et al.
Nature|June 29, 2017
Corrigendum: CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent provirusesBenjamin Descours, Gaël Petitjean, José-Luis López-Zaragoza, et al.
Journal of Clinical Immunology|August 24, 2012
Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patientsDavid Eric Ouedraogo, Alain Makinson, Nils Kuster, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|July 6, 2020
Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoVAhidjo Ayouba, Guillaume Thaurignac, David Morquin, et al.
The Journal of Antimicrobial Chemotherapy|June 30, 2011
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trialSébastien Gallien, Joséphine Braun, Constance Delaugerre, et al.
Pageof 20

Showing results (111-120 of 200) with videos related to

Sort By:
Pageof 20
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2010
Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial)Sébastien Gallien, Valérie Journot, Willy Rozenbaum, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2005
CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strainsYea-Lih Lin, Pierre Portales, Michel Segondy, et al.
Clinical Immunology (Orlando, Fla.)|May 4, 2002
Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cellsAnne Marie Fournier, Jean-Michel Fondere, Catherine Alix-Panabieres, et al.
Immunologic Research|May 3, 2021
Cytokine response following perturbation of the cervicovaginal milieu during HPV genital infectionChristian Selinger, Massilva Rahmoun, Carmen Lia Murall, et al.
Nature|March 16, 2017
CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent provirusesBenjamin Descours, Gaël Petitjean, José-Luis López-Zaragoza, et al.
Nature|June 29, 2017
Corrigendum: CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent provirusesBenjamin Descours, Gaël Petitjean, José-Luis López-Zaragoza, et al.
Journal of Clinical Immunology|August 24, 2012
Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patientsDavid Eric Ouedraogo, Alain Makinson, Nils Kuster, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|July 6, 2020
Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoVAhidjo Ayouba, Guillaume Thaurignac, David Morquin, et al.
The Journal of Antimicrobial Chemotherapy|June 30, 2011
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trialSébastien Gallien, Joséphine Braun, Constance Delaugerre, et al.
Pageof 20